(24R)-24,25-dihydroxyvitamin D₃ | 55721-11-4

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (24R)-24,25-dihydroxyvitamin D₃
• 英文别名: (3R,6R)-6-[(1R,4E,7aR)-4-{2-[(1Z,5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene}-7a-methyl-octahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol；(3R,6R)-6-[(1R,4E,7aR)-4-[(2Z)-2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol
• CAS: 55721-11-4
• 化学式: C₂₇H₄₄O₃
• 分子量: 416.645
• InChiKey: FCKJYANJHNLEEP-AOWQBJNISA-N

物化性质

• 熔点：
  63-65°C
• 沸点：
  474.91°C (rough estimate)
• 密度：
  1.0362 (rough estimate)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险品标志：
  T+
• 危险类别码：
  R28
• 危险品运输编号：
  UN 2811
• 安全说明：
  S28,S36/37,S45
• WGK Germany：
  3
• 危险标志：
  GHS06,GHS08
• 危险性描述：
  H301 + H311,H330,H372
• 危险性防范说明：
  P260,P280,P284,P301 + P310,P310

制备方法与用途

生物活性：Secalciferol是维生素D的代谢物，是一种潜在的参与骨化作用和具有抗炎作用的甾体。

靶点： Human Endogenous Metabolite

反应信息

• 作为产物：
  描述：

  ethyl (24E)-3β-tetrahydropyranyloxycholesta-5,24-dien-26-oate 在 吡啶 、 titanium(IV) isopropylate 、 叔丁基过氧化氢 、 lithium aluminium tetrahydride 、 三氯化铝 、 高氯酸 、 D-(-)-酒石酸二乙酯 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 96.75h， 生成 (24R)-24,25-dihydroxyvitamin D₃
  参考文献：
  名称：

  Koizumi, Naoyuki; Ishiguro, Masaji; Yasuda, Mitsuhiro, Journal of the Chemical Society. Perkin transactions I, 1983, # 7, p. 1401 - 1410

  摘要：

  DOI：

文献信息

• Vitamin d derivatives
  申请人：——

  公开号：US20040019023A1

  公开（公告）日：2004-01-29

  The object of the present invention is to provide vitamin D derivatives that have excellent physiological activities as medicines, particularly as therapeutic agents for skin diseases such as psoriasis, and that have a reduced hypercalcemic effect. The present invention provides a vitamin D derivative of Formula (1): 1 wherein X represents an oxygen atom or a sulfur atom; m represents a number of 1 to 3; R 1 and R 2 each represent a hydrogen atom or an alkyl group; R 4 and R 5 each represent a hydrogen atom or a hydroxyl group, etc.; R 3 represents —YR 8 , etc.; R 6 represents a hydrogen atom, etc.; and R 7 represents a hydrogen atom, etc.

  本发明的目的是提供作为药物的维生素D衍生物，特别是作为治疗银屑病等皮肤疾病的治疗剂，并且具有减少高钙血症作用的维生素D衍生物。 本发明提供了化学式（1）的维生素D衍生物： 1 其中 X代表氧原子或硫原子； m代表1至3的数字； R 1 和R 2 分别代表氢原子或烷基； R 4 和R 5 分别代表氢原子或羟基等； R 3 代表—YR 8 等； R 6 代表氢原子等；以及 R 7 代表氢原子等。
• Novel vitamin D derivatives and process for producing the same
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：EP0184112A2

  公开（公告）日：1986-06-11

  Vitamin D derivatives of the formula where R1, R2 and R3 which may be the same or different each represents a hydrogen atom or a hydroxyl group; X is an oxygen atom, the group of the formula OR4 (where R4 is either a hydrogen atom or a lower alkyl having 4 to 6 carbon atoms that may or may not be substituted by a hydroxyl group), or the group of the formula=N-OR5 (where R5 is either a hydrogen atom or a lower alkyl group having 1 to 5 carbon atoms that may or may not be substituted by a hydroxyl group, an amino group or a lower alkylamino group having 1 to 3 carbon atoms), provided that the carbon atom at 20-position is linked to X by a single bond when X is the group of the formula OR4, and by a double bond in other cases, and a process for preparing the derivatives are disclosed. The derivatives have both the immunoregulating action and the ability to induce differentiation in tumor cells and hence are useful as medicines such as antiallergic agents, antirheumatic agents and antitumor agents.

  本发明涉及一种维生素D衍生物，其化学式为：其中R1、R2和R3可能相同或不同，分别代表氢原子或羟基；X代表氧原子、化学式为OR4的基团（其中R4可以是氢原子或具有4至6个碳原子的低级烷基，可以或不可以被羟基取代），或化学式为N-OR5的基团（其中R5可以是氢原子或具有1至5个碳原子的低级烷基，可以或不可以被羟基、氨基或具有1至3个碳原子的低级烷基氨基取代），但当X为化学式为OR4的基团时，20位碳原子与X之间是通过单键连接的，其他情况下是通过双键连接的。本发明还涉及一种制备该衍生物的方法。该衍生物具有免疫调节作用和诱导肿瘤细胞分化的能力，因此可用作药物，如抗过敏药、抗风湿药和抗肿瘤药。
• 22-Arylsulfonyl-24,25-dihydroxycholestanes and process for preparing the same
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：EP0045524A1

  公开（公告）日：1982-02-10

  24,25-Dihydroxycholestane derivatives of the formula wherein A is a steroid residue and R is an aryl group and a process for preparation of the same are disclosed. The derivatives are intermediates for synthesis of 24,25-dihydroxycholecalciferol having useful physicological activity like that of vitamin D3. 24,25-Dihydroxycholecalciferol can be produced in an industrially advantageous method via the intermediates which are easily prepared from commercially available starting compounds.

  本发明公开了式中 A 为类固醇残基、R 为芳基的 24,25-二羟基胆甾烷衍生物及其制备方法。 这些衍生物是合成 24,25-二羟胆钙化醇的中间体，具有类似维生素 D3 的物理活性。 24,25-二羟基胆钙化醇可以通过这些中间体以一种具有工业优势的方法生产出来，而这些中间体可以很容易地从市售的起始化合物中制备出来。
• Method of improving the shell quality of poultry eggs
  申请人：YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD.

  公开号：EP0033197A2

  公开（公告）日：1981-08-05

  A method of improving the shell quality of poultry eggs so as to increase their resistance against cracking and breakage which consists in the administration to the laying hens of 24R,25-dihydroxy-cholecalciferol (24R,25(OH)2D3) and either 1α-hydroxy-cholecalciferol (la (OH)D3) or 1α,25-dihydroxycholecalciferol (1α,25(OH)2D3).

  一种改善禽蛋蛋壳质量以提高其抗开裂和抗破损能力的方法，包括向产蛋鸡施用 24R,25-二羟基胆钙化醇（24R,25(OH)2D3）和 1α- 羟基胆钙化醇（la (OH)D3）或 1α,25-二羟基胆钙化醇（1α,25(OH)2D3）。
• Novel vitamin D3 derivatives and process for producing the same
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：EP0081793A1

  公开（公告）日：1983-06-22

  There are disclosed 6,19-epidioxyvitamin D3 derivatives which are represented by the formula wherein R1, R2 and R3 are each a hydrogen atom or a hydroxyl group; when R1 is a hydrogen atom, R2 represents a hydroxyl group and R3 is a hydrogen atom or a hydroxyl group; when both R1 and R2 represent a hydroxyl group, R3 is a hydrogen atom or a hydroxyl group; and when R1 is a hydroxyl group and R2 is a hydrogen atom, R3 represents a hydroxyl group. The compounds are highly capable of inducing differentiation of human myeloid leukemia cells with minimum effects on calcium metabolism and are useful as an agent to treat leukemia.

  已公开的 6,19-epidioxyvitamin D3 衍生物由式表示，其中 R1、R2 和 R3 各为氢原子或羟基；当 R1 为氢原子时，R2 代表羟基，R3 为氢原子或羟基；当 R1 和 R2 均代表羟基时，R3 为氢原子或羟基；当 R1 为羟基，R2 为氢原子时，R3 代表羟基。 这些化合物具有很强的诱导人类髓性白血病细胞分化的能力，对钙代谢的影响最小，可用作治疗白血病的药物。